Acción 2105 LAEKNA, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Laekna, Inc.

Acciones

2105

KYG5340S1093

Mercado cerrado - Hong Kong S.E.
Otros sitios de cotización
 10:08:57 25/06/2024 		Varia. Cinco días. Varia. 1 de enero.
5,58 HKD +4,89 % Gráfico intradía de Laekna, Inc. -1,93 % -71,96 %
30/05 Laekna recluta a la primera paciente para el ensayo de fase 3 del tratamiento del cancer de mama en China; las acciones suben un 4 MT
30/05 Laekna, Inc. Anuncia la inscripción de la primera paciente en el ensayo clínico de fase III de LAE002 (AFURESERTIB) más fulvestrant en pacientes con cáncer de mama local avanzado o metastásico HR+/HER2- CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
Laekna Enlists First Patient for Phase 3 Trial for Breast Cancer Treatment in China; Shares Rise 4%
Laekna, Inc. Announces First Patient Enrolled in Phase III Clinical Trial of LAE002 (AFURESERTIB) Plus Fulvestrant in Patients with HR+/HER2- Local Advanced or Metastatic Breast Cancer
Laekna Announces FDA Approval for the Phase III Clinical Trial Protocol of LAE002 (Afuresertib) PLUS LAE001 for the Treatment of Prostate Cancer
US FDA Gives Green Light to Laekna's Phase 3 Trial for Prostate Cancer Drug; Shares Rise 8%
Laekna, Inc. Announces Approval by the U.S. Food and Drug Administrationfor the Phase III Clinical Trial Protocol Of LAE002 (Afuresertib) Plus LAE001 for the Treatment Ofprostate Cancer
Laekna Gets Investigational New Drug Approval from Chinese Regulator for Obesity Drug
Lekna, Inc. Obtains IND Approval from the CDE for LAE102
Laekna Releases 2023 ESG Report
Laekna Scores FDA Nod for Obesity Drug LAE102
Lekna, Inc. Obtains Investigational New Drug Approval from the U.S. Food and Drug Administration for LAE102
Laekna Shrinks Loss in Fiscal 2023
Laekna, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Laekna Submits New Drug Application to US FDA for Anti-Obesity Drug
Lekna, Inc. Submits Investigational New Drug Application for LAE102 for the Treatment of Obtains Treatment of Obtains Treatment to the U.S. Food and Drug Administration
Laekna's LAE102 IND Application Accepted by Chinese Drug Authorities
Laekna, Inc. Announces the Centre for Drug Evaluation of the National Medical Products Administration of China Accepts the Investigational New Drug Application for Lae102
Laekna, Inc. Announces Management Changes
Laekna's Phase 2 Trial for Ovarian Cancer Treatment Shows Reduced Risk of Disease Progression; Shares Plunge 34%
Laekna, Inc. Announces Top-Line Data of the Global MRCT Phase II Registrational Trial (PROFECTA-II) in Both the U.S. and China
Laekna, Inc. Announces Appointment of Chau Kwok Keung as Chief Financial Officer
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción 2105
  4. Noticias Laekna, Inc.
  5. Otros idiomas